Bay­er buys li­cense to Cedil­la pre­clin­i­cal can­cer pro­gram; MEI Phar­ma says no to un­so­licit­ed of­fer

Bay­er has ac­quired ex­clu­sive rights to Cedil­la Ther­a­peu­tics’ pre­clin­i­cal can­cer drug can­di­dates for an undis­closed amount.

Bay­er an­nounced Thurs­day morn­ing that it is ac­quir­ing the li­cense for Cedil­la’s pre­clin­i­cal Cy­clin E1/CDK2 com­plex in­hibitors. Cy­clin E1 ac­ti­vates CDK2, and the two dri­ve can­cer pro­gres­sion and are over­ex­pressed in can­cer cells.

Bay­er did not dis­close what in­di­ca­tions it will be pur­su­ing un­der this part­ner­ship. The deal is struc­tured tra­di­tion­al­ly — Bay­er will pay Cedil­la an undis­closed amount up­front, and the lat­ter is al­so el­i­gi­ble for po­ten­tial de­vel­op­ment and com­mer­cial mile­stones and roy­al­ties. — Lei Lei Wu

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.